Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cognition Therapeutics, Inc

0.3000
-0.0245-7.55%
Post-market: 0.31140.0114+3.80%19:59 EDT
Volume:1.26M
Turnover:401.55K
Market Cap:18.60M
PE:-0.42
High:0.3352
Open:0.3352
Low:0.3000
Close:0.3245
Loading ...

Cognition Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Jun

BRIEF-Cognition Therapeutics Provides Regulatory Update On Zervimesine In Alzheimer’s Disease

Reuters
·
25 Jun

Cognition Therapeutics Inc - to Conduct End-of-Phase 2 Meeting With FDA on July 9, 2025

THOMSON REUTERS
·
25 Jun

Cognition Therapeutics Provides Regulatory Update on Zervimesine (Ct1812) in Alzheimer’s Disease and Dementia With Lewy Bodies (Dlb)

THOMSON REUTERS
·
25 Jun

Cognition Therapeutics Inc. Conducted Annual Stockholders Meeting Virtually

Reuters
·
21 Jun

Cognition Therapeutics Launches Expanded Access Program for Zervimesine

TIPRANKS
·
03 Jun

Cognition Therapeutics Advances to Phase 3 Trials

TIPRANKS
·
02 Jun

Cognition Therapeutics price target lowered to $3 from $5 at H.C. Wainwright

TIPRANKS
·
27 May

Cognition Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $3 From $5

THOMSON REUTERS
·
27 May

Cognition Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
07 May

Cognition Therapeutics Q1 Net Income USD -8.48 Million

THOMSON REUTERS
·
07 May

Cognition Therapeutics Inc: Qtrly Shr Loss $0.14

THOMSON REUTERS
·
07 May

Press Release: Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update

Dow Jones
·
07 May

Cognition Therapeutics Inc expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
02 May

Buy Recommendation for Cognition Therapeutics: Promising Phase 2 Results and Strategic Focus on Alzheimer’s and Dementia Indications

TIPRANKS
·
25 Mar

Cognition Therapeutics Earnings Call: Progress Amid Challenges

TIPRANKS
·
22 Mar

Cognition Therapeutics Inc (CGTX) Q4 2024 Earnings Call Highlights: Strategic Focus on ...

GuruFocus.com
·
21 Mar

Cognition Therapeutics Advances Alzheimer’s and DLB Trials

TIPRANKS
·
21 Mar

Cognition Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
20 Mar

Cognition Therapeutics FY 2024 EPS $(0.86) Misses $(0.76) Estimate

Benzinga
·
20 Mar